期刊文献+

POLD1基因反义RNA对人正常肝细胞和肝癌细胞增殖的影响 被引量:1

Effect of POLD1 gene antisense RNA on proliferation of human normal liver cell and liver cancer cell
下载PDF
导出
摘要 目的分析POLD1基因的反义RNA对人肝癌细胞SMMC-7721和人正常肝细胞HL-7702增殖的影响,以探讨利用POLD1基因反义RNA干预治疗肝癌的可行性。方法构建人POLD1基因的反义RNA表达质粒;将实验分为阴性对照组(转染空质粒的肝癌细胞SMMC-7721和肝细胞HL-7702)、空白对照组(未转染质粒的肝癌细胞SMMC-7721和肝细胞HL-7702)和实验组(转染人POLD1基因反义RNA表达质粒的肝癌细胞SMMC-7721和肝细胞HL-7702);采用CCK-8法分析细胞增殖情况。结果在转染0 h、24 h、48 h、72 h后,3组间肝细胞HL-7702的450 nm处吸光度值(A450值)差异无统计学意义(P>0.05)。实验组肝癌细胞SMMC-7721在转染24 h、48 h、72 h后,A450值均低于空白对照组和阴性对照组(P<0.05)。结论 POLD1基因的反义RNA可在对正常肝细胞生长无明显影响下抑制肝癌细胞的增殖。 Objective To analyze the effect of POLD1 gene antisense RNA on the proliferation of human liver cancer cell SMMC-7721 and human normal liver cell HL-7702 so as to explore the feasibility of POLD1 gene antisense RNA for the treatment of human liver cancer. Methods Expression plasmid with human POLD1 gene antisense RNA was constructed.The experiment consisted of negative control group( HL-7702 cells and SMMC-7721 cells transfected with empty plasmid ) , blank control group ( untransfected HL-7702 cells and SMMC-7721 cells) and experimental group( HL-7702 cells and SMMC-7721 cells transfected with human POLD1 gene antisense RNA) . Cell counting kit-8(CCK-8) assay was used to analyze the cell growth conditions.Results There was no significant difference in the absorbance value(A450 nm) of liver HL-7702 cells 0,24,48 or 72 hours after transfection among three groups(P〉0.05).Compared with blank control group and negative control group, experimental group obtained lower absorbance values ( A450 nm ) of liver cancer cells SMMC-7721 24,48 and 72 hours after transfection(P〈0.05).Conclusion POLD1 gene antisense RNA can inhibit the proliferation of liver cancer cells while the growth of normal hepatocytes is not affected.
出处 《广西医学》 CAS 2015年第7期885-887,共3页 Guangxi Medical Journal
基金 国家自然科学基金(30950028) 广西自然科学基金(2013GXNSFAA019170)
关键词 肝肿瘤 POLD1基因 反义RNA 正常肝细胞 细胞增殖 Livertumor POLD1gene AntisenseRNA Normallivercell Cellproliferation
  • 相关文献

参考文献9

  • 1Karkhanis V, Wang L, Tae S, et al. Protein arginine methl- transferase 7 regulates celluar response to DNA damage by methylating promoter histones H2A and H4 of the polymer- ase 8 catalytic subunit gene, POLD1 [ J ]. J Biol Chem, 2012,287(35) :29 801 -29 814.
  • 2Scherr M, Morgan MA, Eder M. Gene silencing mediated by small interfering RNAs in mammalian ceils [J ]. Curr Med Chem,2003,10 ( 3 ) :245 - 256.
  • 3吴琼,黄文涛,黄怡,徐恒.反义RNA技术对抑制人肝癌细胞SMMC-7721中POLD1基因表达的研究[J].中华肿瘤防治杂志,2013,20(4):241-244. 被引量:5
  • 4孟霞,鲁秦安,唐彩琰,陈树林,张文华.RNAi基因沉默的动力学研究进展[J].动物医学进展,2012,33(1):82-86. 被引量:1
  • 5Bass BL. RNA interference. The short answer [ J ]. Nature, 2001,411(6 836) :428 -429.
  • 6Song E, Lee SK, Wang J, et al. RNA interference targeting Fas protects mice from fulminant hepatitis [ J ]. Nat Med, 2003,9(3) :347 - 351.
  • 7Castanotto D, Rossi JJ. The promises and pitfalls of RNA-in- terference based therapeutics [ J ]. Nature, 2009, 457 (7 228) :426 -433.
  • 8Montgomery MK, Xu S, Fire A. RNA as a target of double- stranded RNA-mediated genetic interference in Caenorhab- ditis elegans [ J ]. Proc Natl Acad Sei USA, 1998,95 ( 26 ) : 15 502 -15 507.
  • 9吴琼,黄文涛,黄怡,廖柳凤,谭晓红,徐恒.RNA干扰技术抑制人肝癌细胞POLD1基因表达的研究[J].广西医学,2014,36(5):549-551. 被引量:2

二级参考文献48

  • 1Caplen N J, Parrish S, Imani F, et al, Specifc inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems [J]. Proe Natl Aead Sci, 2001, 98 (17) : 9742-9747.
  • 2Meister G, Tuschl T. Mechanisms of gene silencing hy doublestranded RNA[J]. Nature, 2004, 431:343-349.
  • 3Rao D D, Vorhies J S, Senzer N, et al. siRNA vs shRNA: similarities and differenees[J]. Adv Drug Deliv Rev, 2009,61 (9) :746-759.
  • 4Takahashi Y, Yamaoka K, Nishikawa M, et al. Quantitative and temporal analysis of gene silencing in tumor cells induced by small interfering RNA or short hairpin RNA expressed from plasmid vectors[J]. Pharm Sci, 2009,98(1) :74-80.
  • 5Vaishnaw A K, Gollob J, Gamba-Vitalo C, et al. A status report on RNAi therapeutics[J]. Silence, 2010,1(1) :14.
  • 6Czech M P, Aouadi M, Tesz G J. RNAi-based therapeutic strategies for metabolic disease[J]. Nat Rev Endocrinol, 2011, 7 : 473-484.
  • 7Watts J K, Deleavey G F, Damha M J. Chemically modified siRNA: tools and applications[J]. Drug Discovery Today, 2008,13(19-20) :842-855.
  • 8Novobrantseva T I, Akine A, Borodovsky A, et al. Delivering silenee..advaneements in developing siRNA therapeutics[J]. Curr Opin Drug Diseov Dev, 2008,11(2) :217-224.
  • 9Endoh T, Ohtsuki T. Cellular siRNA delivery using cell-pene- trating peptides modified for endosomal escape[J]. Advanced Drug Delivery Reviews, 2009,61(9) : 704-709.
  • 10Davis M E, Zuekerman J E, Choi C H J, et al. Evidence of RNAi in humans from systemicallyadministered siRNA via targeted nanoparticles[J]. Nature, 2010,464 : 1067-1070.

共引文献5

同被引文献3

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部